4basebio Launches Enzymatic ssDNA Platform

Summary by AI BETAClose X

4basebio PLC has commercially launched its enzymatic single-stranded DNA (ssDNA) platform, designed to overcome manufacturing and performance limitations of traditional chemical synthesis for genetic therapies. This proprietary process yields high-purity, long-form ssDNA templates up to 10,000 nucleotides with protected ends, enhancing stability and reducing immunogenicity for applications like CRISPR gene editing and cell engineering. The company will present data on this technology, which aims to improve Homology Directed Repair efficiency and cell viability, at the ASGCT Annual Meeting.

Disclaimer*

Companies

4basebio (4BB)
UK 100

Latest directors dealings